Funding for Oxford spinouts jumped more than three-fold year-on-year in terms, while OUI generated four new spinouts on top of 118 disclosures and 19 patents.
University of Oxford spinouts generated a total of £149.9m ($195m) of funding during the second quarter of 2019, more than three times the £41.3m ($56.8m) reported in the same period last year.
The university’s tech transfer office, Oxford University Innovation, set up five businesses during the quarter – four of which were spinouts – compared with three launched during the second quarter of 2018.
OUI’s licensing and ventures unit reported 95 invention disclosures and 19 patent signings for the quarter, down slightly from the 118 disclosures and 21 patents booked at this point last year.
OUI identified the new spinouts as quantum computing technology developer Oxford Ionics, nuclear fusion optimisation code spinout Machine Discovery, mental health data-sharing platform Cristal Health, cancer antibody spinout MiroBio and portable blood monitor manufacturer Oxford Immune Algorithmics.
Among OUI’s other highlights for the quarter was the opening of the university’s new Lab10x research accelerator, which aims to replicate the value of its existing biomedical-focused Lab282 facility in the digital health domain.
The project is a partnership between the university and its venture fund Oxford Sciences Innovation together with digital healthcare provider Sensyne Health and drug discovery company Evotec, the latter of which was also involved with Lab282.
Other events from the quarter include a deal struck with spinout-focused investment firm Osage University Partners enabling the university to become Osage’s first EU-based associated partner, while granting Osage the option of investing and exercising the university’s participation rights in certain Oxford spinouts.
